J&J pauses US rollout of Varipulse heart device

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...
The report, spearheaded by analyst Larry Biegelsen, pointed to conversations with physicians and industry contacts indicating that Johnson & Johnson has possibly paused Varipulse procedures because of ...